TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25845918

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 80

Group type: COMPARATOR
Intervention: FDA ≥30% criterion
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Statistically reliable changes on the VAS for 68% and 95% confidence intervals
Number of subjects: 80
Study: 23700406

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin administration over an 8-week period
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxytocin and its analogs ([Ser4, Ile8]-oxytocin, [Asu1,6]-oxytocin) in mouse models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxytocin or its analogs in streptozotocin-induced diabetic mouse model
Number of subjects: 0
Study: 20530042

Group type: EXPERIMENTAL
Intervention: 12-week supervised exercise intervention
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 12-week supervised exercise intervention followed by 12 weeks of self-administered exercise
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study: 19246445

Group type: EXPERIMENTAL
Intervention: Nicotine patch (21 mg)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Abstinence
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 209
Study: 16997602

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of a single 2 ml dose of hylan G-F 20 into the hip joint under fluoroscopic guidance.
Number of subjects: 56
Study: 15598477

Group type: EXPERIMENTAL
Intervention: Galantamine 8 mg/d
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Galantamine 16 mg/d
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Galantamine 24 mg/d
Number of subjects: 300

Group type: COMPARATOR
Intervention: Community control (untreated)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Galantamine (all doses combined)
Number of subjects: 300
Study: 11903737

Group type: COMPARATOR
Intervention: L-regimen (30 mg lansoprazole u.i.d)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: LC-regimen (30 mg lansoprazole u.i.d. with 200 mg cetraxate q.i.d)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (H. pylori-negative patients)
Number of subjects: 42
Study: 9215029

Group type: EXPERIMENTAL
Intervention: Continuous extradural infusion of ropivacaine 2 mg ml-1 at 4 ml h-1
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Continuous extradural infusion of ropivacaine 2 mg ml-1 at 6 ml h-1
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Continuous extradural infusion of ropivacaine 2 mg ml-1 at 8 ml h-1
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Continuous extradural infusion of ropivacaine 2 mg ml-1 at 10 ml h-1
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 133
Study: 8356864

Group type: EXPERIMENTAL
Intervention: 2 mg.kg‐1 propofol
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.9% saline solution (Control)
Number of subjects: 20
Study: 3301981

Group type: EXPERIMENTAL
Intervention: Light-polymerized fissure sealant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Autopolymerized fissure sealant
Number of subjects: 0
Study: 29067578

Group type: EXPERIMENTAL
Intervention: Transanal low rectal dissection
Number of subjects: 100

Group type: COMPARATOR
Intervention: Laparoscopic low rectal dissection
Number of subjects: 100
Study: 27532874

Group type: EXPERIMENTAL
Intervention: Weekly telephone intervention for three months
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 140
Study: 24972492

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Relaxation intervention
Number of subjects: 207

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 207
Study: 22838094

Group type: EXPERIMENTAL
Intervention: OTC BPO 5.5% formulation with lipohydroxy acid and tretinoin cream 0.025%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prescription clindamycin 1%-BPO 5% gel and tretinoin cream 0.025%
Number of subjects: 0
Study: 20542783

Group type: EXPERIMENTAL
Intervention: Early FFR-guided PCI (invasive group)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Medical treatment (conservative group)
Number of subjects: 121
Study: 18052855

Group type: EXPERIMENTAL
Intervention: Brief behavioral cessation intervention
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intensive behavioral cessation intervention
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 50
Study: 16225497

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg intravenous)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 12373416

Group type: EXPERIMENTAL
Intervention: Flesinoxan 0.5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Flesinoxan 1 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10404500

Group type: EXPERIMENTAL
Intervention: Moderate dose of ethanol (0.5 g.kg‐1)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Alcohol-free drink (control)
Number of subjects: 11
Study: 8524562

Group type: EXPERIMENTAL
Intervention: Community care by glaucoma-trained optometrists with reviews on a six monthly basis
Number of subjects: 405

Group type: COMPARATOR
Intervention: Routine Hospital Eye Services (HES) monitoring
Number of subjects: 405
Study: 2178961

Group type: EXPERIMENTAL
Intervention: Fenoterol 1.6 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 6108129

Group type: EXPERIMENTAL
Intervention: Ketotifen (HC 20-511) 1 mg twice daily for 12 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sodium cromoglycate (SCG) 20 mg four times daily for 12 weeks
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Ketotifen (HC 20-511)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sodium cromoglycate (SCG)
Number of subjects: 35
Study: 31911007

Group type: EXPERIMENTAL
Intervention: SGO Wellness Curriculum
Number of subjects: 73
Study: 29738417

Group type: EXPERIMENTAL
Intervention: Vitamin D (VitD) supplementation 1000 IU VitD3/day for 9 months
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 26741799

Group type: EXPERIMENTAL
Intervention: Dual n-back working memory task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Demanding visuospatial attention task
Number of subjects: 0
Study: 23794382

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) 10 mg IV
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 41
Study: 23163117

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 20517223

Group type: EXPERIMENTAL
Intervention: Cytoflavin, 425 mg, 2 tablets twice a day during 25 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Aminalon, 500 mg, 2 tablets 3 times a day during 25 days
Number of subjects: 60
Study: 18930718

Group type: EXPERIMENTAL
Intervention: Active following (Go-Go trials)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive observation (NoGo-Go trials)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized trials (Rnd)
Number of subjects: 0
Study: 15907400

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lacidipine 6 mg
Number of subjects: 60
Study: 12620596

Group type: EXPERIMENTAL
Intervention: Modified duty
Number of subjects: 165

Group type: COMPARATOR
Intervention: Not working
Number of subjects: 165
Study: 10817549

Group type: EXPERIMENTAL
Intervention: 12.5 mg of rofecoxib once daily
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: 25 mg of rofecoxib once daily
Number of subjects: 784

Group type: COMPARATOR
Intervention: 50 mg of diclofenac 3 times daily
Number of subjects: 784
Study: 8803643

Group type: EXPERIMENTAL
Intervention: Captopril (C 50 mg bid)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ticlopidine (T 250 mg bid)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Captopril plus Ticlopidine (C plus T)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Captopril plus Ticlopidine (C plus T) for twelve months
Number of subjects: 24
Study: 1465278

Group type: EXPERIMENTAL
Intervention: Mitomycin C + high-dose medroxyprogesterone acetate (MMPA)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Cyclophosphamide + doxorubicin + fluorouracil (CAF)
Number of subjects: 34
Study: 6701301

Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 46

Group type: COMPARATOR
Intervention: metrizamide
Number of subjects: 46
Study: 30756462

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30589889

Group type: EXPERIMENTAL
Intervention: Anomalous word neighbours of plausible words
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Unrelated anomalous words
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Anomalous word neighbour condition
Number of subjects: 30

Group type: COMPARATOR
Intervention: Plausible condition
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Independent component analysis (ICA)
Number of subjects: 30
Study: 26833461

Group type: EXPERIMENTAL
Intervention: Rectal administration of 125‐mg, 250‐mg, or 500‐mg AZM suppository
Number of subjects: 5

Group type: COMPARATOR
Intervention: Oral administration of AZM 500‐mg tablet
Number of subjects: 5
Study: 25785316

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg/kg bolus before intubation, followed by 2 mg/kg/h continuous infusion)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Saline (same dosage as lidocaine)
Number of subjects: 55
Study: 22233205

Group type: EXPERIMENTAL
Intervention: Ginsenoside‐Rd
Number of subjects: 390

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study: 20381159

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 87

Group type: COMPARATOR
Intervention: Venlafaxine
Number of subjects: 87
Study: 18377121

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Cognitive Therapy only (CPT-C)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Written Accounts (WA)
Number of subjects: 150
Study: 15488899

Group type: EXPERIMENTAL
Intervention: Selective hippocampal damage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MTL damage including perirhinal cortex
Number of subjects: 0
Study: 12740799

Group type: EXPERIMENTAL
Intervention: Modeling group (2/3 of patients)
Number of subjects: 38876

Group type: COMPARATOR
Intervention: Cross-validation group (1/3 of patients)
Number of subjects: 38876
Study: 10333154

Group type: EXPERIMENTAL
Intervention: ePTFE membrane implantation
Number of subjects: 33

Group type: COMPARATOR
Intervention: No material implanted (control group)
Number of subjects: 33
Study: 8706484

Group type: EXPERIMENTAL
Intervention: Amphotericin B in lipid emulsion (20% intralipid)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Amphotericin B in 5% dextrose in water
Number of subjects: 60
Study: 1908314

Group type: EXPERIMENTAL
Intervention: buserelin/hMG
Number of subjects: 373

Group type: COMPARATOR
Intervention: CC/hMG
Number of subjects: 373
Study: 6478567

Group type: EXPERIMENTAL
Intervention: Home exercise training (n = 66)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Group exercise training (n = 61)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Treadmill testing at 3 weeks without subsequent training (n = 34)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control group (treadmill testing for the first time at 26 weeks, n = 37)
Number of subjects: 198
Study: 30265171

Group type: EXPERIMENTAL
Intervention: Amniotic membrane stem cell‐conditioned medium (AMSC‐CM)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 48
Study: 30168415

Group type: EXPERIMENTAL
Intervention: Namilumab 80 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Namilumab 150 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Namilumab 300 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 26742607

Group type: EXPERIMENTAL
Intervention: ProBalance Programme (n=27)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Wait-list control group (n=25)
Number of subjects: 52
Study: 24930436

Group type: EXPERIMENTAL
Intervention: adapalene in combination with a moisturizer (heparinoid)
Number of subjects: 100

Group type: COMPARATOR
Intervention: adapalene alone
Number of subjects: 100
Study: 19473997

Group type: COMPARATOR
Intervention: HSV suppressive treatment (placebo-controlled)
Number of subjects: 1305

Group type: EXPERIMENTAL
Intervention: Recent sex
Number of subjects: 1305

Group type: EXPERIMENTAL
Intervention: Using cloths or cotton wool for menstrual hygiene
Number of subjects: 1305

Group type: EXPERIMENTAL
Intervention: HIV
Number of subjects: 1305

Group type: EXPERIMENTAL
Intervention: Inserting substances to dry the vagina for sex
Number of subjects: 1305
Study: 15051595

Group type: EXPERIMENTAL
Intervention: Diet-induced weight loss
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 316

Group type: COMPARATOR
Intervention: Healthy lifestyle control
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Diet plus exercise
Number of subjects: 316
Study: 12365866

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 80

Group type: COMPARATOR
Intervention: Diltiazem
Number of subjects: 80
Study: 8981380

Group type: EXPERIMENTAL
Intervention: Previous trial with incorrect response
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Previous LVF target (word)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Previous LVF target (nonword)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Same response category as unattended stimulus in previous trial
Number of subjects: 0
Study: 7653742

Group type: EXPERIMENTAL
Intervention: Acrivastine 8 mg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 3602020

Group type: EXPERIMENTAL
Intervention: 500 mg naproxen twice daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: 400 mg pirprofen twice daily
Number of subjects: 60
Study: 31576959

Group type: EXPERIMENTAL
Intervention: NSD plus MTZ (400 mg) and AMX (500 mg) three times a day for 14 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: NSD plus placebo
Number of subjects: 40
Study: 29921143

Group type: EXPERIMENTAL
Intervention: Mantram repetition therapy
Number of subjects: 173

Group type: COMPARATOR
Intervention: Present-centered therapy
Number of subjects: 173
Study: 27730819

Group type: EXPERIMENTAL
Intervention: Oral sodium nitrate treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24478129

Group type: EXPERIMENTAL
Intervention: Neutrophil/Lymphocyte Ratio (NLR) in patients with HP infection
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Neutrophil/Lymphocyte Ratio (NLR) in symptomatic HP patients with grade 4 gastritis
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Neutrophil/Lymphocyte Ratio (NLR) as severity of gastritis increases
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cut-off level for NLR
Number of subjects: 50
Study: 23147874

Group type: EXPERIMENTAL
Intervention: Pressure Volume Loop (PV-L) closure technique
Number of subjects: 140

Group type: COMPARATOR
Intervention: Fixed preset pressure technique
Number of subjects: 140

Group type: COMPARATOR
Intervention: Pilot balloon palpation technique
Number of subjects: 140
Study: 18084052

Group type: EXPERIMENTAL
Intervention: Self-directed format
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Group format
Number of subjects: 575
Study: 17975151

Group type: EXPERIMENTAL
Intervention: 12-peptide vaccine containing a mixture of 12 peptides from melanocytic differentiation proteins and cancer‐testis antigens
Number of subjects: 0

Group type: COMPARATOR
Intervention: 4-peptide vaccine with only melanocytic differentiation peptides
Number of subjects: 0
Study: 14727004

Group type: EXPERIMENTAL
Intervention: Ketamine (0.4 mg kg(‐1))
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Ketamine (0.8 mg kg(‐1))
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 11808908

Group type: EXPERIMENTAL
Intervention: EMLA patch
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 161
Study: 9748796

Group type: EXPERIMENTAL
Intervention: AC (doxorubicin, cyclophosphamide)
Number of subjects: 106

Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate, 5-fluorouracil)
Number of subjects: 106
Study: 8153291

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (AmBisome) 1-1.38 mg/kg/day for 21 days
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (AmBisome) 3 mg/kg/day for 10 days
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (AmBisome) 100 mg (1.38-1.85 mg/kg) daily for 21 days
Number of subjects: 31
Study: 3046404

Group type: EXPERIMENTAL
Intervention: terbutaline delivered by a nebuhaler
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: terbutaline delivered by a tube spacer
Number of subjects: 15

Group type: COMPARATOR
Intervention: pressurized aerosol
Number of subjects: 15
Study: 29118060

Group type: EXPERIMENTAL
Intervention: sTNFR-1/2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: sE-selectin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: fibrinogen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PAI-1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: biomarkers (sTNFR-1/2, sE-selectin, PAI-1, and fibrinogen)
Number of subjects: 0
Study: 26817735

Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 7007

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7007
Study: 26324220

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 666

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 666

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 666
Study: 24156925

Group type: EXPERIMENTAL
Intervention: Culturally responsive health promotion program (CHP-K) consisting of 8 weeks of Qi exercise and face-to-face counseling on physical and psychological factors.
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (not specified in detail in the abstract).
Number of subjects: 63
Study: 21843837

Group type: EXPERIMENTAL
Intervention: Lateral wedge insoles (5 degrees) made of high density ethyl vinyl acetate, worn bilaterally every day for 12 months.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Flat control insoles made of low density ethyl vinyl acetate, worn bilaterally every day for 12 months.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Lateral wedge insoles (5 degrees)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Flat control insoles
Number of subjects: 200
Study: 18355744

Group type: EXPERIMENTAL
Intervention: Educational intervention (didactic session and posting criteria for asthma severity classification)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (data from 2002-2003)
Number of subjects: 12
Study: 16977645

Group type: EXPERIMENTAL
Intervention: Caregiver skill training intervention
Number of subjects: 131
Study: 12639652

Group type: EXPERIMENTAL
Intervention: Periprostatic injection of 10 mL of 2% lidocaine solution without epinephrine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (10 mL of 0.9% NaCl)
Number of subjects: 100
Study: 11189013

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin for up to 4 weeks
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Metoprolol (intravenous then oral) for up to 4 weeks
Number of subjects: 20000

Group type: COMPARATOR
Intervention: Placebo for up to 4 weeks
Number of subjects: 20000
Study: 9202354

Group type: EXPERIMENTAL
Intervention: Right ventricle to axillary patch configuration (12.7 +/- 5.9 J)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Right ventricle to superior vena cava plus axillary patch configuration (9.8 +/- 5.2 J)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Right ventricle to pectoral can configuration (9.2 +/- 5.1 J)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Right ventricle to array configuration (5.6 +/- 3.6 J)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Low-energy endocardial defibrillation (< or =10 J)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Low-energy endocardial defibrillation (5 J)
Number of subjects: 16
Study: 8246533

Group type: EXPERIMENTAL
Intervention: Tissue-type plasminogen activator and fibrin monomers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Retransfusion of shed blood
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fibrinogen degradation products and tissue-type plasminogen activator stimulating activity
Number of subjects: 0
Study: 3963028

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (200 mg per day)
Number of subjects: 822

Group type: COMPARATOR
Intervention: Aspirin (4,000 mg per day)
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 822

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 822
Study: 30917364

Group type: EXPERIMENTAL
Intervention: Statin therapy with intensive SBP goal < 120 mm Hg
Number of subjects: 2646

Group type: COMPARATOR
Intervention: Statin therapy with standard SBP goal < 140 mm Hg
Number of subjects: 2646

Group type: COMPARATOR
Intervention: Non-statin therapy with intensive SBP goal < 120 mm Hg
Number of subjects: 2646

Group type: COMPARATOR
Intervention: Non-statin therapy with standard SBP goal < 140 mm Hg
Number of subjects: 2646
Study: 29277378

Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla-300)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin glargine 100 U/mL (Gla-100)
Number of subjects: 0
Study: 27530088

Group type: EXPERIMENTAL
Intervention: Tedizolid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Linezolid
Number of subjects: 0
Study: 24433061

Group type: EXPERIMENTAL
Intervention: Aliskiren (150 mg/day) for 12 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Angiotensin II receptor antagonists (ARBs)
Number of subjects: 18
Study: 22538670

Group type: EXPERIMENTAL
Intervention: Laparoscopic transabdominal preperitoneal repair (TAPP)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Lichtenstein repair
Number of subjects: 185
Study: 20541347

Group type: EXPERIMENTAL
Intervention: Population-based AAA screening
Number of subjects: 4